← back to search

Cristina Olagüe

Gene Therapy Laboratory · FR
Area of research
Epidemiology · Genetics
Research interest
Research interests include Transduction (biophysics), Medicine, Genetic enhancement, Biology, Acute intermittent porphyria, and Porphyria.
h-index
citations
132
works
5
NIH funding
primary concept
email

Recent publications

Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
EMBO Molecular Medicine 2024cited by 21position: middledoi
Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure
Oncotarget 2016cited by 13position: middledoi
A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type I IFN Response
Journal of Innate Immunity 2015cited by 14position: middledoi
Safety and Liver Transduction Efficacy of rAAV5- <i>cohPBGD</i> in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria
Human Gene Therapy 2013cited by 61position: middledoi
IL12-Mediated Liver Inflammation Reduces the Formation of AAV Transcriptionally Active Forms but Has No Effect over Preexisting AAV Transgene Expression
PLoS ONE 2013cited by 23position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Gloria González‐Aseguinolaza · Gene Therapy Laboratory5 papers (2013–2024)África Vales · Gene Therapy Laboratory4 papers (2013–2024)Jesús Prìeto · Gene Therapy Laboratory3 papers (2013–2015)Marianna Di Scala · Gene Therapy Laboratory3 papers (2013–2016)Irene Gil-Fariña · Knowledge Unlatched (Germany)2 papers (2013–2016) · 1 papers (2013–2013)Nerea Zabaleta · Harvard Stem Cell Institute1 papers (2024–2024)Florence Salmon · Novartis (Switzerland)1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013)Christof von Kalle · Luxembourg Institute of Health1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2024–2024)Toni Cathomen · University of Freiburg1 papers (2024–2024) · 1 papers (2024–2024) · 1 papers (2024–2024)Federico Mingozzi · Spark Therapeutics (United States)1 papers (2013–2013) · 1 papers (2013–2013)Juán José Gavira · Navarre Institute of Health Research1 papers (2013–2013)